Why Veeva Systems (VEEV) is on investors’ radar right now
Veeva Systems (VEEV) is drawing attention after a mixed stretch for the stock, with gains over the past week and day contrasting with weaker returns over the past month and past 3 months.
See our latest analysis for Veeva Systems.
At a share price of $173.98, Veeva’s short term momentum has cooled, with a 30 day share price return of 11% and a 90 day share price return of 21.39% contributing to a 1 year total shareholder return of 18.58%, which points to sentiment that has weakened over time.
If you are weighing Veeva’s recent pullback against other healthcare technology names, it can help to scan a wider field of life sciences and medical AI software peers using 36 healthcare AI stocks
With Veeva trading at $173.98, a value score of 3, and an indicated 36.09% intrinsic discount, the key question is whether you are seeing a genuine opportunity or a price that already reflects future growth.
Most Popular Narrative: 35.8% Undervalued
The most widely followed narrative puts Veeva Systems' fair value at $270.93 compared with the last close at $173.98, framing the current price as well below the modeled outcome and setting up a thesis that leans heavily on product adoption and margin potential.
The resolution of the long-standing dispute with IQVIA removes critical data interoperability barriers, enabling Veeva to fully integrate industry-leading datasets into its Commercial Cloud, which should materially expand its addressable market, improve product adoption across multiple commercial applications, and accelerate top-line revenue growth over the next several years.
Veeva's rapid progress embedding advanced AI agents directly within its Vault platform across both R&D and Commercial suites positions it as an essential workflow and automation partner amid the rising complexity of personalized medicine, genomics, and data-driven trials, potentially supporting higher pricing power, platform stickiness, and net margin expansion in the medium to long term.
Curious what kind of revenue runway, margin profile, and future earnings power sit behind that valuation gap? The narrative leans on a specific growth path and a premium future earnings multiple that are anything but conservative.
Result: Fair Value of $270.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in competition in core CRM and the risk that customers adopt new AI tools more slowly than this upbeat scenario assumes.
Find out about the key risks to this Veeva Systems narrative.
Another View: What P/E Is Telling You
The earlier narrative leans on a large gap to fair value, but the current P/E ratio of 31.3x tells a more cautious story. It sits above both the global Healthcare Services industry at 28.9x and Veeva’s peer average of 28.5x, and even above the fair ratio estimate of 29x.
That richer multiple suggests the market already prices in a premium, which can mean less room for error if growth or margins fall short. The question is how comfortable you are paying above both peers and the fair ratio for this earnings profile.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of optimism and caution around Veeva is clear. If you want to move quickly, review the positives for yourself with 4 key rewards
Looking for more investment ideas?
If Veeva has your attention, do not stop there. Use focused stock lists to spot other opportunities that match the kind of profile you care about most.
- Target long term compounding potential by scanning companies that combine quality with attractive valuations using the 58 high quality undervalued stocks.
- Strengthen your portfolio’s income stream by reviewing businesses offering higher yields through the 13 dividend fortresses.
- Focus on resilience and capital protection by checking companies with lower risk profiles through the 68 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com